MA45554A - Fusions de binucléase optimisées. - Google Patents

Fusions de binucléase optimisées.

Info

Publication number
MA45554A
MA45554A MA045554A MA45554A MA45554A MA 45554 A MA45554 A MA 45554A MA 045554 A MA045554 A MA 045554A MA 45554 A MA45554 A MA 45554A MA 45554 A MA45554 A MA 45554A
Authority
MA
Morocco
Prior art keywords
binuclease
fusions
optimized
optimized binuclease
binuclease fusions
Prior art date
Application number
MA045554A
Other languages
English (en)
Inventor
Chris Gabel
Sanjay Patel
James Arthur Posada
Weihong Yu
Original Assignee
Resolve Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolve Therapeutics Llc filed Critical Resolve Therapeutics Llc
Publication of MA45554A publication Critical patent/MA45554A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
MA045554A 2016-07-01 2017-06-30 Fusions de binucléase optimisées. MA45554A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357756P 2016-07-01 2016-07-01

Publications (1)

Publication Number Publication Date
MA45554A true MA45554A (fr) 2019-05-08

Family

ID=59399475

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045554A MA45554A (fr) 2016-07-01 2017-06-30 Fusions de binucléase optimisées.

Country Status (10)

Country Link
US (2) US20190241878A1 (fr)
EP (2) EP4410378A3 (fr)
JP (3) JP7308034B2 (fr)
CN (1) CN109790526A (fr)
AU (2) AU2017290389B2 (fr)
CA (1) CA3029627A1 (fr)
DK (1) DK3478830T3 (fr)
HR (1) HRP20240603T1 (fr)
MA (1) MA45554A (fr)
WO (1) WO2018005954A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091939A1 (fr) 2009-11-02 2011-05-05 University Of Washington Compositions therapeutiques a base de nucleases et methodes
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
WO2020142740A1 (fr) * 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Traitement de la maladie de sjögren à l'aide de protéines de fusion de type nucléases
EP4090736A4 (fr) * 2020-01-11 2024-02-21 Yale University Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3
WO2021252470A2 (fr) * 2020-06-08 2021-12-16 Yale University Compositions et méthodes de traitement et/ou de prévention de la coagulopathie et/ou de la septicémie chez des patients souffrant d'infections bactériennes et/ou virales
CN112322607B (zh) * 2020-11-20 2023-03-28 江南大学 一种融合型腈水合酶及其应用
WO2022178090A2 (fr) * 2021-02-19 2022-08-25 Theripion, Inc. Polypeptides de fusion dnase, compositions et méthodes associées

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2011A (en) 1841-03-18 Appabatxts for piling saws
US154516A (en) 1874-08-25 Improvement in pistons for steam-engines
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
FR2560212B1 (fr) 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5559212A (en) 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
IL88377A (en) 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO1992018626A1 (fr) 1991-04-17 1992-10-29 Laboratoire Europeen De Biotechnologie POLYPEPTIDES HYDROSOLUBLES AYANT UNE HAUTE AFFINITE POUR LES INTERFERONS α ET $g(b)
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
EP0601052B1 (fr) 1991-08-30 1996-10-16 Genentech, Inc. Procede therapeutique servant a traiter le diabete sucre insulinodependant
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1993015722A1 (fr) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
EP0563487A1 (fr) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
CA2142007C (fr) 1992-08-11 2007-10-30 Robert Glen Urban Peptides immunomodulateurs
US5423269A (en) 1992-11-24 1995-06-13 Gunderson, Inc. Railroad well car body including side sill reinforcing walkway structure
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
IL107378A (en) 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP0799244A1 (fr) 1995-10-16 1997-10-08 Unilever N.V. Analogue de fragment d'anticorps bifonctionnel ou bivalent
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
CA2262405A1 (fr) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
US6083477A (en) 1996-10-17 2000-07-04 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US20030083461A1 (en) 1997-06-16 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5840296A (en) 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A
US6280991B1 (en) 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
JP4601163B2 (ja) 1997-12-19 2010-12-22 メルク・セローノ・ソシエテ・アノニム Ｉｆｎａｒ２／ｉｆｎ複合体
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030175778A1 (en) 1998-06-05 2003-09-18 Jian Ni Interferon Receptor HKAEF92
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
WO2000022093A2 (fr) 1998-09-23 2000-04-20 Cleveland Clinic Foundation Nouveaux genes stimules ou reprimes par l'interferon
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
US6239257B1 (en) 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
EP1141024B1 (fr) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
US6175003B1 (en) 1999-09-10 2001-01-16 Alfacell Corporation Nucleic acids encoding ribonucleases and methods of making them
WO2001026608A2 (fr) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Vaccins a base d'adn codant pour un antigene associe a un domaine se liant a cd40
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
EP2322644A1 (fr) 2000-06-28 2011-05-18 GlycoFi, Inc. Procédé de production de glycoprotéines modifiées
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CN101612402A (zh) 2001-01-09 2009-12-30 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002096948A2 (fr) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Anticorps tetravalents modifies et procedes d'utilisation
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
JP4586310B2 (ja) 2001-07-04 2010-11-24 株式会社Ｉｈｉ セラミックス複合部材の製造方法
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20060040262A1 (en) 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
IL147414A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003097877A1 (fr) 2002-05-17 2003-11-27 Riken Procede de detection d'un polymorphisme genique
AU2003276711A1 (en) 2002-06-14 2003-12-31 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3502133A1 (fr) 2002-09-27 2019-06-26 Xencor, Inc. Variantes fc optimisées et leurs procédés de génération
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1578367A4 (fr) 2002-11-01 2012-05-02 Genentech Inc Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
EP1587540B1 (fr) 2003-01-09 2021-09-15 MacroGenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
PL1631312T3 (pl) 2003-04-23 2009-02-27 Squibb & Sons Llc Kompozycje i sposoby terapii choroby zapalenia jelit
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20040266993A1 (en) 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1664116A4 (fr) 2003-08-22 2009-06-03 Biogen Idec Inc Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2541523A1 (fr) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Sequence d'adn minime isolant la chromatine et son utilisation dans l'expression de proteine
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CN1902222A (zh) 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
UA86605C2 (ru) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Антитело, которое содержит вариант исходного человеческого fс-участка
US7544487B2 (en) 2004-02-13 2009-06-09 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2005115477A2 (fr) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Conjugues de ribonuclease non naturelle utilises en tant qu'agents cytotoxiques
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
EP1791866A2 (fr) 2004-08-11 2007-06-06 Trubion Pharmaceuticals, Inc. Proteines de fusion a domaine de liaison
JP2006071409A (ja) 2004-09-01 2006-03-16 Kansai Tlo Kk シェーグレン症候群診断キット
WO2006031994A2 (fr) 2004-09-14 2006-03-23 Xencor, Inc. Domaines fc monomeres des immunoglobulines
CN101056654A (zh) 2004-10-07 2007-10-17 苏黎士大学 用于预防和治疗银屑病的i型干扰素阻断剂
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
DE102005009219A1 (de) 2005-02-25 2006-08-31 Martin-Luther-Universität Halle-Wittenberg Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
WO2006105062A2 (fr) 2005-03-29 2006-10-05 Verenium Corporation Régions fc d'anticorps altérées et utilisations de celles-ci
CA2605781A1 (fr) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
DE602006017705D1 (de) 2005-06-16 2010-12-02 Wisconsin Alumni Res Found Zytotoxische ribonukleasevarianten
JP2008546391A (ja) 2005-06-16 2008-12-25 ウイスコンシン アラムニ リサーチ ファンデーション 細胞傷害性リボヌクレアーゼ変異株
US7732167B2 (en) 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US7608395B2 (en) 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
BRPI0617688A2 (pt) 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
BRPI0710011A2 (pt) 2006-04-14 2011-08-02 Trubion Pharmaceuticals Inc proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
WO2007122511A2 (fr) 2006-04-21 2007-11-01 Mab-Factory Gmbh Conjugué anticorps-rnase
WO2007136789A2 (fr) 2006-05-19 2007-11-29 Medimmune, Inc. Procédés destinés à la prévention, au traitement ou au soulagement d'une maladie respiratoire aggravée via des mécanismes immunitaires innés
GB0611444D0 (en) 2006-06-09 2006-07-19 Medical Res Council Technology Rnase H2 complex and genes therefor
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
JP5102833B2 (ja) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
US8198063B1 (en) 2006-09-12 2012-06-12 Pro Zyme, Inc Rapid deglycosylation of glycoproteins
EP1905841A1 (fr) 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 comme marqueur du lupus érythemateux
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
CA2682605A1 (fr) 2007-04-18 2008-10-30 Zymogenetics, Inc. Fc a chaine simple, procedes de fabrication et procedes de traitement
CA2686861A1 (fr) 2007-05-03 2008-11-13 Medimmune, Llc Marqueurs pharmacodynamiques alpha-induit d'interferon
EP2158318A2 (fr) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Régions fc simple chaîne, polypeptides de liaison comportant de telles régions, et procédés correspondants
WO2008150485A2 (fr) 2007-05-29 2008-12-11 Wyeth Compositions thérapeutiques et procédés
RU2010100638A (ru) 2007-06-12 2011-07-20 УАЙТ ЭлЭлСи (US) Композиции и способы лечения, направленные против cd20
WO2009023386A2 (fr) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Peptides de liaison comprenant un domaine de liaison spécifique c-terminal
WO2009015345A1 (fr) 2007-07-25 2009-01-29 Amgen Inc. Compositions pharmaceutiques comprenant des protéines de fusion fc
CA2720628A1 (fr) 2007-07-26 2009-01-29 Novagen Holding Corporation Proteines de fusion
CN104004739A (zh) 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
CA2705542A1 (fr) 2007-11-13 2009-05-22 Sapphire Energy, Inc. Production de polypeptides hybrides fc dans des algues eucaryotes
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2009126944A1 (fr) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Produits d’immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
JP5563572B2 (ja) 2008-07-23 2014-07-30 ハンミ サイエンス カンパニー リミテッド 三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
AU2009296393A1 (en) 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
US20100273220A1 (en) 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
US10837020B2 (en) 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
EP3248618A1 (fr) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Suppression de l'immunité innée permettant l'administration répétée de longues molécules d'arn
EP2445936A1 (fr) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
CA3091939A1 (fr) 2009-11-02 2011-05-05 University Of Washington Compositions therapeutiques a base de nucleases et methodes
BR112012013330A2 (pt) 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
KR101913440B1 (ko) 2010-03-02 2018-10-30 교와 핫꼬 기린 가부시키가이샤 개변 항체 조성물
WO2011124718A1 (fr) 2010-04-09 2011-10-13 Novozymes A/S Dérivés et variants d'albumine
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
BR112013012213A2 (pt) 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
WO2012068636A1 (fr) 2010-11-26 2012-05-31 The University Of Melbourne Procédés et compositions comprenant des antagonistes de la signalisation médiée par l'interféron type 1 visant à réduire la réponse neuro-inflammatoire dans le système nerveux central
WO2012088302A2 (fr) 2010-12-22 2012-06-28 Abbott Laboratories Protéines de liaison à une demi-immunoglobuline et leurs utilisations
TWI529163B (zh) 2011-01-25 2016-04-11 陶氏農業科學公司 用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法
MX350200B (es) 2011-02-01 2017-08-30 Genmab As Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
CN106417184A (zh) 2011-02-25 2017-02-22 重组股份有限公司 经遗传修饰的动物及其生成方法
CA2832389A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2 et cd3
WO2012143523A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2
US20140170148A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
EP3505528B1 (fr) 2011-04-21 2020-11-25 Ionis Pharmaceuticals, Inc. Modulation de l'expression du virus de l'hépatite b (vhb)
CA2834626A1 (fr) 2011-04-29 2012-11-01 University Of Washington Compositions a base de nuclease therapeutique et procedes associes
WO2013003475A1 (fr) 2011-06-27 2013-01-03 Cellscript, Inc. Inhibition d'une réponse immunitaire innée
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
WO2013059299A1 (fr) 2011-10-17 2013-04-25 The Uab Research Foundation Anticorps dirigés contre divers sous-types d'interféron, complexe ternaire interféron/récepteur d'interféron et utilisations associées
PL2771364T3 (pl) 2011-10-27 2020-01-31 Genmab A/S Wytwarzanie heterodimerycznych białek
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2013180295A1 (fr) 2012-06-01 2013-12-05 日本電信電話株式会社 Procédé de traitement de transfert de paquets et dispositif de traitement de transfert de paquets
KR20210130270A (ko) 2012-06-13 2021-10-29 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
US9499634B2 (en) * 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
GB2503883A (en) 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
EP2872170A4 (fr) * 2012-07-13 2016-06-22 Zymeworks Inc Hétérodimères asymétriques bispécifiques comprenant des produits de recombinaison anti-cd3
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
EP3004167B1 (fr) 2013-05-30 2018-07-25 Kiniksa Pharmaceuticals, Ltd. Protéines de liaison à l'antigène du récepteur de l'oncostatine m
US11098105B2 (en) 2013-05-31 2021-08-24 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
ES2759252T3 (es) * 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
JP6873701B2 (ja) 2014-01-15 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変されているＦｃ領域変異体
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
WO2016069889A1 (fr) * 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Hybrides nucléase-transferrine à visée thérapeutique et procédés associés
WO2016087648A1 (fr) 2014-12-05 2016-06-09 Universität Für Bodenkultur Wien Immunoglobulines présentant des domaines ch3 hétérologues incorporés entraînant une demi-vie prolongée
CA2963615A1 (fr) 2014-12-05 2016-06-09 Merck Patent Gmbh Anticorps a domaine echange
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
CA2984458A1 (fr) 2015-05-13 2016-11-17 Zymeworks Inc. Constructions de liaison a un antigene ciblant her2
US9693229B2 (en) 2015-11-05 2017-06-27 International Business Machines Corporation Logical subscriber identification module (SIM)
CN107007606B (zh) 2016-02-04 2021-10-26 南京舒鹏生物科技有限公司 一种用于干燥综合症预防及治疗的药物及其组合
CN109153728A (zh) 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
WO2017185177A1 (fr) 2016-04-25 2017-11-02 Zymeworks Inc. Procédés d'utilisation de constructions de liaison à l'antigène bispécifiques ciblant her2
PL3448419T3 (pl) 2016-04-29 2023-09-04 Pfizer Inc. Przeciwciała interferonu beta i ich zastosowania
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
AU2017315146A1 (en) 2016-08-26 2019-04-11 Sanofi Multispecific antibodies facilitating selective light chain pairing
US10072296B2 (en) 2016-09-19 2018-09-11 The Charlotte Mecklenburg Hospital Authority Compositions and methods for sjögren's syndrome
JP6349003B1 (ja) 2017-03-17 2018-06-27 東洋ビーネット株式会社 耐熱性ルシフェラーゼ
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
WO2020142740A1 (fr) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Traitement de la maladie de sjögren à l'aide de protéines de fusion de type nucléases
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins

Also Published As

Publication number Publication date
WO2018005954A2 (fr) 2018-01-04
JP2019530430A (ja) 2019-10-24
JP7308034B2 (ja) 2023-07-13
CN109790526A (zh) 2019-05-21
HRP20240603T1 (hr) 2024-07-19
EP3478830A2 (fr) 2019-05-08
EP3478830B1 (fr) 2024-04-10
US20190241878A1 (en) 2019-08-08
JP2024026334A (ja) 2024-02-28
AU2017290389A1 (en) 2019-02-14
JP2022153588A (ja) 2022-10-12
AU2017290389B2 (en) 2024-09-26
CA3029627A1 (fr) 2018-01-04
DK3478830T3 (da) 2024-05-21
US12077790B2 (en) 2024-09-03
EP4410378A2 (fr) 2024-08-07
EP4410378A3 (fr) 2024-10-09
WO2018005954A3 (fr) 2018-03-29
AU2024219520A1 (en) 2024-10-03
US20220112474A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
DOP2018000256A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
CL2015002226S1 (es) Automóvil.
CL2015002104S1 (es) Automovil.
CL2015002833S1 (es) Automovil.
CL2014001893S1 (es) Vehiculo.
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
BR112017012364A2 (pt) pré-tratamento rápido.
CL2017000337S1 (es) Maquina de afeitar.
MA45554A (fr) Fusions de binucléase optimisées.
FR3023988B3 (fr) .
CL2017002511S1 (es) Contenedor.
CL2015002137S1 (es) Automovil.
CL2017002510S1 (es) Contenedor.
IT201600084952A1 (it) Coglifrutta.
DK3215792T3 (da) Brænder.
ES1150114Y (es) Abarcón.
IT201600117182A1 (it) Ribobinatrice.
DK3339109T3 (da) Låseenhed.
ES1151158Y (es) Somier plegable.
ITUB20169875A1 (it) Indumento.
IT201700118826A1 (it) giandujamarcobava.it
IT201600132795A1 (it) Capsulismo.
CL2018001670S1 (es) Automóvil.
ES1166583Y (es) Juego de construcción.
CL2018000448S1 (es) Envase.